Mycophenolate mofetil in nonlupus glomerulonephropathy

Mycophenolate mofetil (MMF) initially found widespread use in the immunoprophylaxis of rejection in organ transplantation. It has subsequently been used in lupus glomerulonephritis, where early studies have shown it to be effective in induction and maintenance therapy. The randomized studies have mo...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2005-01, Vol.14 (1_suppl), p.39-41
Main Authors: Karim, MY, Abbs, IC
Format: Article
Language:English
Subjects:
Glomerulonephritis - drug therapy
Humans
Immunosuppressive Agents - pharmacology
Immunosuppressive Agents - therapeutic use
Mycophenolic Acid - analogs & derivatives
Mycophenolic Acid - pharmacology
Mycophenolic Acid - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c288t-8c023060232af628ec9837d5c0598594da85714a4c6ca8f6e5b8e85d327152a33
cites cdi_FETCH-LOGICAL-c288t-8c023060232af628ec9837d5c0598594da85714a4c6ca8f6e5b8e85d327152a33
container_end_page 41
container_issue 1_suppl
container_start_page 39
container_title Lupus
container_volume 14
creator Karim, MY
Abbs, IC
description Mycophenolate mofetil (MMF) initially found widespread use in the immunoprophylaxis of rejection in organ transplantation. It has subsequently been used in lupus glomerulonephritis, where early studies have shown it to be effective in induction and maintenance therapy. The randomized studies have mostly studied small groups of patients and their conclusions do need to be confirmed in larger studies. MMF has also been used in small numbers of patients in a variety of nonlupus glomerulopathies, which have different underlying immunopathology as well as clinical course, including IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, hepatitis-C-associated glomerulonephritis and even Goodpasture's syndrome. In this article, we discuss its use in such nonlupus glomerular diseases.
doi_str_mv 10.1177/096120330501400108
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_744718596</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_096120330501400108</sage_id><sourcerecordid>744718596</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-8c023060232af628ec9837d5c0598594da85714a4c6ca8f6e5b8e85d327152a33</originalsourceid><addsrcrecordid>eNp9kD1PwzAQQC0EoqXwBxhQJphCz9_OiCq-pCIWmCPXcdpUThzsZOi_x1UrMSB1uRvu3RseQrcYHjGWcg6FwAQoBQ6YAWBQZ2iKmZR5upBzNN0D-Z6YoKsYtwBAcSEu0QRzBbSgMEXiY2d8v7Gdd3qwWetrOzQua7qs850b-zFma-dbG0bnO9tvgu_1sNldo4tau2hvjnuGvl-evxZv-fLz9X3xtMwNUWrIlQFCQaRBdC2IsqZQVFbcAC8UL1ilFZeYaWaE0aoWlq-UVbyiRGJONKUz9HDw9sH_jDYOZdtEY53TnfVjLCVjEieTSOT9SVJIkWpQnEByAE3wMQZbl31oWh12JYZy37X83zU93R3t46q11d_LMWQC5gcg6rUtt34MXepySvkLQkp-vQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67696131</pqid></control><display><type>article</type><title>Mycophenolate mofetil in nonlupus glomerulonephropathy</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)</source><creator>Karim, MY ; Abbs, IC</creator><creatorcontrib>Karim, MY ; Abbs, IC</creatorcontrib><description>Mycophenolate mofetil (MMF) initially found widespread use in the immunoprophylaxis of rejection in organ transplantation. It has subsequently been used in lupus glomerulonephritis, where early studies have shown it to be effective in induction and maintenance therapy. The randomized studies have mostly studied small groups of patients and their conclusions do need to be confirmed in larger studies. MMF has also been used in small numbers of patients in a variety of nonlupus glomerulopathies, which have different underlying immunopathology as well as clinical course, including IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, hepatitis-C-associated glomerulonephritis and even Goodpasture's syndrome. In this article, we discuss its use in such nonlupus glomerular diseases.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/096120330501400108</identifier><identifier>PMID: 15803930</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Glomerulonephritis - drug therapy ; Humans ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Mycophenolic Acid - analogs &amp; derivatives ; Mycophenolic Acid - pharmacology ; Mycophenolic Acid - therapeutic use</subject><ispartof>Lupus, 2005-01, Vol.14 (1_suppl), p.39-41</ispartof><rights>2005 Edward Arnold (Publishers) Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c288t-8c023060232af628ec9837d5c0598594da85714a4c6ca8f6e5b8e85d327152a33</citedby><cites>FETCH-LOGICAL-c288t-8c023060232af628ec9837d5c0598594da85714a4c6ca8f6e5b8e85d327152a33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15803930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karim, MY</creatorcontrib><creatorcontrib>Abbs, IC</creatorcontrib><title>Mycophenolate mofetil in nonlupus glomerulonephropathy</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Mycophenolate mofetil (MMF) initially found widespread use in the immunoprophylaxis of rejection in organ transplantation. It has subsequently been used in lupus glomerulonephritis, where early studies have shown it to be effective in induction and maintenance therapy. The randomized studies have mostly studied small groups of patients and their conclusions do need to be confirmed in larger studies. MMF has also been used in small numbers of patients in a variety of nonlupus glomerulopathies, which have different underlying immunopathology as well as clinical course, including IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, hepatitis-C-associated glomerulonephritis and even Goodpasture's syndrome. In this article, we discuss its use in such nonlupus glomerular diseases.</description><subject>Glomerulonephritis - drug therapy</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Mycophenolic Acid - analogs &amp; derivatives</subject><subject>Mycophenolic Acid - pharmacology</subject><subject>Mycophenolic Acid - therapeutic use</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAQQC0EoqXwBxhQJphCz9_OiCq-pCIWmCPXcdpUThzsZOi_x1UrMSB1uRvu3RseQrcYHjGWcg6FwAQoBQ6YAWBQZ2iKmZR5upBzNN0D-Z6YoKsYtwBAcSEu0QRzBbSgMEXiY2d8v7Gdd3qwWetrOzQua7qs850b-zFma-dbG0bnO9tvgu_1sNldo4tau2hvjnuGvl-evxZv-fLz9X3xtMwNUWrIlQFCQaRBdC2IsqZQVFbcAC8UL1ilFZeYaWaE0aoWlq-UVbyiRGJONKUz9HDw9sH_jDYOZdtEY53TnfVjLCVjEieTSOT9SVJIkWpQnEByAE3wMQZbl31oWh12JYZy37X83zU93R3t46q11d_LMWQC5gcg6rUtt34MXepySvkLQkp-vQ</recordid><startdate>200501</startdate><enddate>200501</enddate><creator>Karim, MY</creator><creator>Abbs, IC</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>200501</creationdate><title>Mycophenolate mofetil in nonlupus glomerulonephropathy</title><author>Karim, MY ; Abbs, IC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-8c023060232af628ec9837d5c0598594da85714a4c6ca8f6e5b8e85d327152a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Glomerulonephritis - drug therapy</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Mycophenolic Acid - analogs &amp; derivatives</topic><topic>Mycophenolic Acid - pharmacology</topic><topic>Mycophenolic Acid - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karim, MY</creatorcontrib><creatorcontrib>Abbs, IC</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karim, MY</au><au>Abbs, IC</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mycophenolate mofetil in nonlupus glomerulonephropathy</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2005-01</date><risdate>2005</risdate><volume>14</volume><issue>1_suppl</issue><spage>39</spage><epage>41</epage><pages>39-41</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Mycophenolate mofetil (MMF) initially found widespread use in the immunoprophylaxis of rejection in organ transplantation. It has subsequently been used in lupus glomerulonephritis, where early studies have shown it to be effective in induction and maintenance therapy. The randomized studies have mostly studied small groups of patients and their conclusions do need to be confirmed in larger studies. MMF has also been used in small numbers of patients in a variety of nonlupus glomerulopathies, which have different underlying immunopathology as well as clinical course, including IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, hepatitis-C-associated glomerulonephritis and even Goodpasture's syndrome. In this article, we discuss its use in such nonlupus glomerular diseases.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>15803930</pmid><doi>10.1177/096120330501400108</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0961-2033
ispartof Lupus, 2005-01, Vol.14 (1_suppl), p.39-41
issn 0961-2033
1477-0962
language eng
recordid cdi_proquest_miscellaneous_744718596
source SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)
subjects Glomerulonephritis - drug therapy
Humans
Immunosuppressive Agents - pharmacology
Immunosuppressive Agents - therapeutic use
Mycophenolic Acid - analogs & derivatives
Mycophenolic Acid - pharmacology
Mycophenolic Acid - therapeutic use
title Mycophenolate mofetil in nonlupus glomerulonephropathy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-09T02%3A01%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mycophenolate%20mofetil%20in%20nonlupus%20glomerulonephropathy&rft.jtitle=Lupus&rft.au=Karim,%20MY&rft.date=2005-01&rft.volume=14&rft.issue=1_suppl&rft.spage=39&rft.epage=41&rft.pages=39-41&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/096120330501400108&rft_dat=%3Cproquest_cross%3E744718596%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c288t-8c023060232af628ec9837d5c0598594da85714a4c6ca8f6e5b8e85d327152a33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67696131&rft_id=info:pmid/15803930&rft_sage_id=10.1177_096120330501400108&rfr_iscdi=true